<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACETADOTE- acetylcysteineÂ injection, solutionÂ </strong><br>Cumberland Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ACETADOTE safely and effectively.  See full prescribing information for ACETADOTE.<br>ACETADOTE (acetylcysteine) Injection<br>Initial U.S. Approval: 2004
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Acetadote is an antidote for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen (<a href="#s1">1</a>)
 </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">The total dose of Acetadote is 300 mg/kg given as 3 separate doses and administered over a total of 21 hrs. Please refer to the guidelines below for dose preparation based upon patient weight.
 </p>
<p class="Highlighta"><span class="Bold">Dosing for patients who weigh 5 kg to 20 kg (<a href="#s5">2.1</a>):</span> </p>
<p class="Highlighta"><span class="Underline">Loading Dose</span>: 150 mg/kg diluted in 3 mL/kg of diluent* administered over 1 hr
 </p>
<p class="Highlighta"><span class="Underline">Second Dose</span>: 50 mg/kg diluted in 7 mL/kg of diluent* administered over 4 hrs
 </p>
<p class="Highlighta"><span class="Underline">Third Dose</span>: 100 mg/kg diluted in 14 mL/kg of diluent* administered over 16 hrs
 </p>
<p class="Highlighta"><span class="Bold">Dosing for patients who weigh 21 kg to 40 kg (<a href="#s5">2.1</a>):</span> </p>
<p class="Highlighta"><span class="Underline">Loading Dose</span>: 150 mg/kg diluted in 100 mL of diluent* administered over 1 hr
 </p>
<p class="Highlighta"><span class="Underline">Second Dose</span>: 50 mg/kg diluted in 250 mL of diluent* administered over 4 hrs
 </p>
<p class="Highlighta"><span class="Underline">Third Dose</span>: 100 mg/kg diluted in 500 mL of diluent* administered over 16 hrs
 </p>
<p class="Highlighta"><span class="Bold">Dosing for patients who weigh 41 kg to 100 kg (<a href="#s5">2.1</a>):</span> </p>
<p class="Highlighta"><span class="Underline">Loading Dose</span>: 150 mg/kg diluted in 200 mL of diluent* administered over 1 hr
 </p>
<p class="Highlighta"><span class="Underline">Second Dose</span>: 50 mg/kg diluted in 500mL of diluent* administered over 4 hrs
 </p>
<p class="Highlighta"><span class="Underline">Third Dose</span>: 100 mg/kg diluted in 1000 mL of diluent* administered over 16 hrs
 </p>
<p class="Highlighta">*Acetadote is compatible with the following diluents; 5% Dextrose in Water, 0.45% Sodium Chloride Injection, and Sterile Water for Injection
 </p>
<p class="Highlighta"><span class="Bold">Dosing for patients who weigh more than 100 kg (<a href="#s5">2.1</a>):</span> </p>
<p class="Highlighta">No specific studies have been conducted to evaluate the use of or necessity of dosing adjustments in patients weighing over 100 kg. Limited information is available regarding the dosing requirements of patients that weigh more than 100 kg. The dose of Acetadote recommended in these patients should be a loading dose of 15,000 mg infused over one hour followed by a first maintenance dose of 5,000 mg over 4 hrs and a second maintenance dose of 10,000 mg over 16 hrs
 </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Each single-dose vial contains 6 g/30 mL (200 mg/mL), Acetadote Injection (<a href="#s14">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with previous <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> to acetylcysteine (<a href="#s15">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li> Monitor as acute <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the skin may occur; usually associated with the loading dose; often resolves spontaneously despite continued infusion (<a href="#s17">5.1</a>)
</li>
<li> Monitor for serious <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>; infusion may be interrupted until treatment of anaphylactoid symptoms has been initiated (<a href="#s17">5.1</a>)
</li>
<li> Should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or where there is a history of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> (<a href="#s18">5.2</a>)
</li>
<li> Total volume administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction (<a href="#s19">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence greater than 2%) are <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>/<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (<a href="#s21">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Cumberland Pharmaceuticals Inc. at 1-877-484-2700 or FDA at 1-800-FDA-1088 or
</span><span class="Bold Underline">www.fda.gov/medwatch</span>.
 </p>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">No drug-drug interaction studies have been conducted (<a href="#s24">7</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">Pregnancy: This drug should be used during pregnancy only if clearly needed (<a href="#s26">8.1</a>)
 </p>
<p class="Highlighta">Nursing Mothers: Unknown if drug is excreted in human milk (<a href="#s28">8.3</a>)
 </p>
<p class="Highlighta">Pediatric Use: See dose adjustment for patients less than 40 kg (<a href="#s4">2</a>)
 </p>
</div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Acetaminophen Assays Interpretation and Methodology â€“ Acute Ingestion
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Acetaminophen Assays Interpretation and Methodology â€“ Repeated Supratherapeutic Ingestion
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Administration Instructions (Threeâ€“Bag Method: Loading, Second and Third Dose)
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Volume Adjustment: Patients less than 40 kg and Requiring Fluid Restriction
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Monitoring patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Volume Adjustment: Patients less than 40 kg and Requiring Fluid Restriction
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric use
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17   PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">Acetadote is an antidote for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> incidences are divided into two types; Acute Ingestion or Repeated Supratherapeutic Ingestion (RSI). [<span class="Italics">see Dosage and Administration (<a href="#s4">2</a>) and Acetaminophen Assays â€“ Interpretation and Methodology-(Acute or Repeated Supratherapeutic Ingestion) (<a href="#s2">1.1</a>, <a href="#s3">1.2</a>)</span>].
</p>
<p>On admission for suspected acute acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a serum blood sample should be drawn at least 4 hours after ingestion to determine the acetaminophen level and will serve as a basis for determining the need for treatment with acetylcysteine. If the patient presents after 4 hours post-ingestion, the serum acetaminophen sample should be determined immediately.
</p>
<p>Acetadote should be administered within 8 hours from acetaminophen ingestion for maximal protection against hepatic injury for patients whose serum acetaminophen levels <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> above the â€œpossibleâ€? toxicity line on the Rumack-Matthew nomogram (line connecting 150 mcg/mL at 4 hours with 37.5 mcg/mL at 12 hours); [<span class="Italics">see Acetaminophen Assays â€“ Interpretation and Methodology (<a href="#s2">1.1</a>, <a href="#s3">1.2</a>)</span>].  If the time of ingestion is unknown, or the serum acetaminophen level is not available, cannot be interpreted, or is not available within the 8 hour time interval from acetaminophen ingestion, Acetadote should be administered immediately if 24 hours or less have elapsed from the reported time of ingestion of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of acetaminophen, regardless of the quantity reported to have been ingested.
</p>
<p>The <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), alanine aminotranferase (ALT, SGPT), bilirubin, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, creatinine, blood urea nitrogen (BUN), blood glucose, and electrolytes also should be determined in order to monitor hepatic and renal function and electrolyte and fluid balance.
</p>
<p><span class="Bold">NOTE:</span>  The critical ingestion-treatment interval for maximal protection against severe hepatic injury is between 0 â€“ 8 hours.  Efficacy diminishes progressively after 8 hours and treatment initiation between 15 and 24 hours post-ingestion of acetaminophen yields limited efficacy.  However, it does not appear to worsen the condition of patients and it should not be withheld, since the reported time of ingestion may not be correct.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Acetaminophen Assays Interpretation and Methodology â€“ Acute Ingestion
</h2>
<p class="First">The acute ingestion of acetaminophen in quantities of 150 mg/kg or greater may result in hepatic toxicity.  However, the reported history of the quantity of a drug ingested as an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is often inaccurate and is not a reliable guide to therapy of the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Therefore, plasma or serum acetaminophen concentrations, determined as early as possible, but no sooner than four hours following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, are essential in assessing the potential risk of hepatotoxicity.  If an assay for acetaminophen cannot be obtained, it is necessary to assume that the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is potentially toxic.
</p>
<p><span class="Bold">Interpretation of Acetaminophen Assays</span></p>
<ol class="Arabic">
<li>When results of the plasma acetaminophen assay are available, refer to the nomogram in <a href="#fig1">Figure 1</a> to determine if plasma concentration is in the potentially toxic range.  Values above the line connecting 200 mcg/mL at 4 hours with 50 mcg/mL at 12 hours (probable line) are associated with a probability of hepatic toxicity if an antidote is not administered.
</li>
<li>If the predetoxification plasma level is above the line connecting 150 mcg/mL at 4 hours with 37.5 mcg/mL at 12 hours (possible line), continue with maintenance doses of acetylcysteine.  It is better to err on the safe side and thus this line, defining possible toxicity, is plotted 25% below the line defining probable toxicity.
</li>
<li>If the predetoxification plasma level is below the line connecting 150 mcg/mL at 4 hours with 37.5 mcg/mL at 12 hours (possible line), there is minimal risk of hepatic toxicity, and acetylcysteine treatment may be discontinued.
</li>
</ol>
<p>Estimating Potential for Hepatotoxicity:  The following depiction of the Rumack-Matthew nomogram has been developed to estimate the probability that plasma levels in relation to intervals post-ingestion will result in hepatotoxicity.
</p>
<p>The Rumack-Matthew nomogram may underestimate the risk for hepatotoxicity in some patients with risk factors such as <span class="product-label-link" type="condition" conceptid="435243" conceptname="Alcohol dependence">chronic alcoholism</span>, <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, or CYP2E1 enzyme inducing drugs (e.g., isoniazid).
</p>
<p><a name="fig1"></a><span class="Bold">Figure 1. Rumack-Matthew Nomogram</span></p>
<p><a name="f01"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39&amp;name=ace16-0008-01.jpg"></p>
<p>Figure 1. Michael J Hodgman, Alexander R Garrard, A Review of Acetaminophen <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>. <span class="Italics">Crit Care Clin.</span> 28 (2012) 499-516.
</p>
<p>Stephen J. Wolf, Kennon Heard, et.al, Clinical Policy: Critical Issues in the Management of Patients Presenting to the Emergency Department with Acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>. <span class="Italics">Ann Emerg Med</span>. 2007:50:292-313.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Acetaminophen Assays Interpretation and Methodology â€“ Repeated Supratherapeutic Ingestion
</h2>
<p class="First">Repeated Supratherapeutic Ingestion (RSI) is defined as ingestion of acetaminophen at doses higher than those recommended for extended periods of time. The nomogram does not apply to patients with RSI.  Treatment is based on the acetaminophen and elevated AST/ALT levels indicative of potential toxicity due to acetaminophen.  For specific treatment information regarding the clinical management of repeated supratherapeutic acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, please contact your regional poison center at 1-800-222-1222, or alternatively, a special health professional assistance line for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> at 1-800-525-6115.
</p>
<p><span class="Bold">Figure 2. Acetadote Treatment Flow Chart</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39&amp;name=ace16-0008-02.jpg">
</div>
<p><span class="Sup">1</span>Acetaminophen levels drawn less than 4 hours post-ingestion may be misleading.
</p>
<p><span class="Sup">2</span>With an extended-release preparation, an acetaminophen level drawn less than 8 hours post-ingestion may be misleading.  Draw a second level at 4 to 6 hours after the initial level. If either <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> above the toxicity line, acetylcysteine treatment should be initiated.
</p>
<p><span class="Sup">3</span>Acetylcysteine may be withheld until acetaminophen assay results are available as long as initiation of treatment is not delayed beyond 8 hours post-ingestion.  If more than 8 hours post-ingestion, start acetylcysteine treatment immediately.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The total dose of Acetadote is 300 mg/kg given as 3 separate doses and administered over a total of 21 hours.  Please refer to the guidelines below for dose preparation based upon patient weight.  The total volume administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction (see <a href="#t1">Tables 1</a> and <a href="#t2">2</a>).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Administration Instructions (Threeâ€“Bag Method: Loading, Second and Third Dose)
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Bold">Dosing for Patients who weigh 5 kg to 20 kg (<a href="#t1">Table 1</a>):</span></p>
<p><span class="Underline">Loading Dose</span>: 150 mg/kg diluted in 3 mL/kg of diluent* administered over 1 hr
</p>
<p><span class="Underline">Second Dose</span>: 50 mg/kg diluted in 7 mL/kg of diluent* administered over 4 hrs
</p>
<p><span class="Underline">Third Dose</span>: 100 mg/kg diluted in 14 mL/kg of diluent* administered over 16 hrs
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Three Bag Method Dosage Guide by Weight in Patients 5 kg to 20 kg
</span></caption>
<col align="left" width="13.343%">
<col align="left" width="16.271%">
<col align="left" width="13.014%">
<col align="left" width="16.271%">
<col align="left" width="12.871%">
<col align="left" width="15.643%">
<col align="left" width="12.586%">
<tfoot><tr class="First Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Bold">*</span>Acetadote is compatible with the following diluents; 5% Dextrose in Water, 0.45% Sodium Chloride Injection, and Sterile Water for Injection.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">Body<br>Weight (kg)
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Bag 1 (loading dose):<br><br>150 mg/kg in 3 mL/kg of diluent* infused over 1 hour
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Bag 2 (second dose)<br><br>50 mg/kg in 7mL/kg of diluent* infused over 4 hours
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Bag 3 (third dose)<br><br>100 mg/kg diluted in               14 mL/kg of diluent* infused over 16 hours
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Acetadote Total Dose
</td>
<td class="Botrule Rrule" align="center" valign="top">Diluent<br>volume
</td>
<td class="Botrule Rrule" align="center" valign="top">Acetadote Total Dose
</td>
<td class="Botrule Rrule" align="center" valign="top">Diluent<br>volume
</td>
<td class="Botrule Rrule" align="center" valign="top">Acetadote Total Dose
</td>
<td class="Botrule Rrule" align="center" valign="top">Diluent<br>volume
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">5 kg
</td>
<td class="Botrule Rrule" align="center" valign="top">750 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">15 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">250 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">35 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">70 mL
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">10 kg
</td>
<td class="Botrule Rrule" align="center" valign="top">1,500 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">30 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">500 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">70 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">1,000 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">140mL
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">15 kg
</td>
<td class="Botrule Rrule" align="center" valign="top">2,250 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">45 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">750 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">105mL
</td>
<td class="Botrule Rrule" align="center" valign="top">1,500 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">210mL
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">20 kg
</td>
<td class="Botrule Rrule" align="center" valign="top">3,000 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">60 mL
</td>
<td class="Botrule Rrule" align="center" valign="top">1,000mg
</td>
<td class="Botrule Rrule" align="center" valign="top">140mL
</td>
<td class="Botrule Rrule" align="center" valign="top">2,000 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">280mL
</td>
</tr>
</tbody>
</table>
<p>See also Section <a href="#s11">2.2</a> Volume Adjustment: Patients less than 40 kg and Requiring Fluid Restriction
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Bold">Dosing for patients who weigh 21 kg to 40 kg (<a href="#t2">Table 2</a>):</span></p>
<p><span class="Underline">Loading Dose</span>: 150 mg/kg diluted in 100 mL of diluent* administered over 1 hr
</p>
<p><span class="Underline">Second Dose</span>: 50 mg/kg diluted in 250 mL of diluent* administered over 4 hrs
</p>
<p><span class="Underline">Third Dose</span>: 100 mg/kg diluted in 500 mL of diluent* administered over 16 hrs
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. Three Bag Method Dosage Guide by Weight in Patients 21 kg to 40 kg
</span></caption>
<col align="left" width="13.403%">
<col align="left" width="27.782%">
<col align="left" width="29.407%">
<col align="left" width="29.407%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Bold">*</span>Acetadote is compatible with the following diluents; 5% Dextrose in Water 0.45% Sodium Chloride Injection, and Sterile Water for Injection.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">Body<br>Weight (kg)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Bag 1 (loading dose):<br><br>150 mg/kg in 100 mL of diluent* infused over 1 hr
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Bag 2 (second dose)<br><br>50 mg/kg in 250 mL of diluent* infused over 4 hrs
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Bag 3 (third dose)<br><br>100 mg/kg in 500 mL of diluent* infused over 16 hrs
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Acetadote<br>Total Dose (mg)
</td>
<td class="Botrule Rrule" align="center" valign="top">Acetadote<br>Total Dose (mg)
</td>
<td class="Botrule Rrule" align="center" valign="top">Acetadote<br>Total Dose (mg)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">21 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">3,150 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">1,050 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">2,100 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">30 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">4,500 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">1,500 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">3,000 mg
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">40 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">6,000 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">2,000 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">4,000 mg
</td>
</tr>
</tbody>
</table>
<p>See also Section <a href="#s11">2.2</a> Volume Adjustment: Patients less than 40 kg and Requiring Fluid Restriction.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.1.3"></a><p></p>
<p class="First"><span class="Bold">Dosing for patients who weigh 41 kg to 100 kg (<a href="#t3">Table 3</a>):</span></p>
<p><span class="Underline">Loading Dose</span>: 150 mg/kg diluted in 200 mL of diluent<span class="Bold"><span class="Sup">*</span></span> administered over 1 hr
</p>
<p><span class="Underline">Second Dose</span>: 50 mg/kg diluted in 500 mL of diluent* administered over 4 hrs
</p>
<p><span class="Underline">Third Dose</span>: 100 mg/kg diluted in 1000 mL of diluent* administered over 16 hrs
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3. Three Bag Method Dosage Guide by Weight in Patients 41 kg to 100 kg
</span></caption>
<col align="left" width="13.403%">
<col align="left" width="29.407%">
<col align="left" width="29.407%">
<col align="left" width="27.782%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">*Acetadote is compatible with the following diluents; 5% Dextrose 0.45% Sodium Chloride Injection, and Sterile Water for Injection.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">Body<br>Weight (kg)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Bag 1 (loading dose):<br><br>150 mg/kg diluted in 200 mL of diluent* infused over 1 hr<br>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Bag 2 (second dose):<br><br>50 mg/kg diluted in 500 mL of diluent* infused over 4 hrs<br>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Bag 3 (third dose):<br><br>100 mg/kg diluted in 1000 mL of diluent* infused over 16 hrs<br>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Acetadote Total Dose (mg)
</td>
<td class="Botrule Rrule" align="center" valign="top">Acetadote Total Dose (mg)
</td>
<td class="Botrule Rrule" align="center" valign="top">Acetadote Total Dose (mg)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">41 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">6,150 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">2,050 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">4,100 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">50 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">7,500 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">2,500 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">5,000 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">60 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">9,000 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">3,000 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">6,000 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">70 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">10,500 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">3,500 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">7,000 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">80 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">12,000 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">4,000 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">8,000 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">90 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">13,500 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">4,500 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">9,000 mg
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">100 kg
</td>
<td class="Botrule Rrule" align="right" valign="top">15,000 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">5,000 mg
</td>
<td class="Botrule Rrule" align="right" valign="top">10,000 mg
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.1.4"></a><p></p>
<p class="First"><span class="Bold">Patients Weighing More Than 100 kg</span></p>
<p>No specific studies have been conducted to evaluate the use of or necessity of dosing adjustments in patients weighing over 100 kg. Limited information is available regarding the dosing requirements of patients that weigh more than 100 kg. The dose of Acetadote recommended in these patients should be a loading dose of 15,000 mg infused over a period of one hour followed by a first maintenance dose of 5,000 mg over 4 hours and a second maintenance dose of 10,000 mg over 16 hours (See <a href="#t3">Table 3</a>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.1.5"></a><p></p>
<p class="First"><span class="Bold">Continued Therapy beyond 21 Hours</span></p>
<p>While there is no clinical trial data to support infusions beyond 21 hours there is literature that supports continued infusion of acetylcysteine in some rare instances. In cases of suspected massive <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, or with concomitant ingestion of other substances, or in patients with preexisting liver disease, the absorption and/or the half-life of acetaminophen may be prolonged, in such cases consideration should be given to the need for continued infusion of N-acetylcysteine beyond 21 hours. Acetaminophen levels and ALT/AST &amp; INR should be checked before the end of the 21-hour infusion. If acetaminophen levels are still detectable, or in cases in which the ALT/AST are still increasing or the INR remains elevated, the infusion should be continued, and the treating physician should contact a US regional poison center at 1-800-222-1222, or alternatively, a â€œspecial health professional assistance line for acetaminophen overdoseâ€? at 1-800-525-6115 for assistance with dosing recommendations.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Volume Adjustment: Patients less than 40 kg and Requiring Fluid Restriction
</h2>
<p class="First">The total volume administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction.  To avoid <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>, the volume of diluent should be reduced as clinically needed. If the volume of the infusion is not adjusted, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> can occur, potentially resulting in <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  [<span class="Italics">see Dosage and Administration (<a href="#s4">2</a>)</span>].
</p>
<p>As Acetadote is hyperosmolar (2600 mOsmol/L), caution is advised when the diluent volume is decreased as the hyperosmolarity of the solution is increased. See <a href="#t4">Table 4</a> below for examples.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4. Acetadote Concentration and Osmolarity
</span></caption>
<col align="left" width="23.925%">
<col align="left" width="25.250%">
<col align="left" width="23.575%">
<col align="left" width="27.250%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">*Osmolarity should be adjusted to a physiologically safe level, (generally not less than 150mOsmol/L in children).
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Acetadote Concentration (mg/mL)
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">Osmolarity in Â½ Normal Saline
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">Osmolarity in D5W
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">Osmolarity in Sterile Water for Injection
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">7 mg/mL
</td>
<td class="Botrule Rrule" align="left" valign="top">245 mOsmol/L
</td>
<td class="Botrule Rrule" align="left" valign="top">343 mOsmol/L
</td>
<td class="Botrule Rrule" align="left" valign="top">91 mOsmol/L*
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">24 mg/m/L
</td>
<td class="Botrule Rrule" align="left" valign="top">466 mOsmol/L
</td>
<td class="Botrule Rrule" align="left" valign="top">564 mOsmol/L
</td>
<td class="Botrule Rrule" align="left" valign="top">312 mOsmol/L
</td>
</tr>
</tbody>
</table>
<p>Single dose vial, preservative-free, discard unused portion.  If vial was previously opened, do not use for intravenous administration.
</p>
<p>Stability studies indicate that the diluted solution is stable for 24 hours at controlled room temperature.
</p>
<p>Note:  The color of Acetadote may turn from essentially colorless to a slight pink or purple once the stopper is punctured.  The color change does not affect the quality of the product.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">No data are available to determine if a dose adjustment in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is required.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.4"></a><p></p>
<h2>2.4 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Although there was a threefold increase in acetylcysteine plasma concentrations in patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>, no data are available to determine if a dose adjustment in these patients is required.  The published medical literature does not indicate that the dose of acetylcysteine in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be reduced.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s14"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Each single dose vial contains 6g/30mL (200 mg/mL) of Acetadote (acetylcysteine) Injection. Acetadote is sterile and can be used for intravenous administration.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s15"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">Acetadote is contraindicated in patients with previous <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> to acetylcysteine.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s16"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in a patient with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, have been reported in patients administered acetylcysteine intravenously.
</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the skin may occur in patients receiving acetylcysteine intravenously. These reactions usually occur 30 to 60 minutes after initiating the infusion and often resolve spontaneously despite continued infusion of acetylcysteine. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> (defined as the occurrence of an acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> during acetylcysteine administration including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, and/or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>), have been observed in patients receiving intravenous acetylcysteine for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and occurred soon after initiation of the infusion [<span class="Italics">see Adverse Reactions (<a href="#s21">6.1</a>)</span>].  If a reaction to acetylcysteine involves more than simply <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the skin, it should be treated as an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>. This usually entails administering antihistaminic drugs and in severe cases may require administration of epinephrine. In addition, the acetylcysteine infusion may be interrupted until treatment of the anaphylactoid symptoms has been initiated and then carefully restarted.  If the <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> returns upon reinitiation of treatment or increases in severity, intravenous acetylcysteine should be discontinued and alternative patient management should be considered.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Monitoring patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>
</h2>
<p class="First">Acetadote should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or where there is a history of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Volume Adjustment: Patients less than 40 kg and Requiring Fluid Restriction
</h2>
<p class="First">The total volume administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction.  To avoid <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>, the volume of diluent should be reduced as needed [<span class="Italics">see Dosage and Administration (<a href="#s4">2</a>)</span>].  If volume is not adjusted <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> can occur, potentially resulting in <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
</p>
<p>For specific treatment information regarding the clinical management of acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, please contact your regional poison center at 1-800-222-1222, or alternatively, a special health professional assistance line for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> at 1-800-525-6115.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s20"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>In the literature the most frequently reported adverse reactions attributed to intravenous acetylcysteine administration were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.  The frequency of adverse reactions has been reported to be between 0.2% and 20.8%, and they most commonly occur during the initial loading dose of acetylcysteine.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Loading Dose/Infusion Rate Study</span></p>
<p>The incidence of drug-related adverse reactions occurring within the first 2 hours following acetylcysteine administration reported in a randomized study in patients with acetaminophen <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is presented in <a href="#t5">Table 5</a> by preferred term.  In this study patients were randomized to a 15-minute or a 60-minute loading dose regimen.
</p>
<p>Within the first 2 hours following intravenous acetylcysteine administration, 17% developed an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (18% in the 15-minute treatment group; 14% in the 60-minute treatment group) in this randomized, open-label, multi-center clinical study conducted in Australia to compare the rates of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> between two rates of infusion for the intravenous acetylcysteine loading dose [<span class="Italics">see Warnings (<a href="#s16">Section 5</a>) and Clinical Studies - Loading Dose/Infusion Rate Study (<a href="#s50">Section 14</a>)</span>].
</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5. Incidence of Drug-Related Adverse Reactions Occurring Within the First 2 Hours Following Study Drug Administration by Preferred Term:  Loading Dose/Infusion Rate Study
</span></caption>
<col align="left" width="23.752%">
<col align="left" width="8.714%">
<col align="left" width="8.714%">
<col align="left" width="10.893%">
<col align="left" width="8.714%">
<col align="left" width="8.714%">
<col align="left" width="8.714%">
<col align="left" width="13.071%">
<col align="left" width="8.714%">
<tfoot><tr class="First Last"><td align="left" colspan="9" valign="top"><p class="First Footnote"><span class="Italics">Unkn=Unknown</span></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Treatment Group
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="middle">15-min
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="middle">60-min
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Number of Patients
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">n=109
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">n=71
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">5 (5%)
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">2 (3%)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="right" valign="middle"><span class="Italics">Severity:</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> NOS
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">4 (4%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">2 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">16 (15%)
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">7 (10%)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="right" valign="middle"><span class="Italics">Severity:</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">6 (6%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> NOS
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">2 (2%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">11 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">2 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 (6%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">20 (18%)
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">10 (14%)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="right" valign="middle"><span class="Italics">Severity:</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">2 (2%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">6 (6%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">11 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">4 (6%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">5 (7%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">2 (2%)
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">2 (3%)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="right" valign="middle"><span class="Italics">Severity:</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhoea</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">Rhonchi</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Skin &amp; subcutaneous tissue disorders
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">6 (6%)
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">5 (7%)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="right" valign="middle"><span class="Italics">Severity:</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">2 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> NOS
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">3 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">2 (2%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">3 (4%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">2 (2%)
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle">3 (4%)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="right" valign="middle"><span class="Italics">Severity:</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Unkn</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Mild</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Moderate</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Italics">Severe</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â  Â  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">2 (3%)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Postmarketing Safety Study</span></p>
<p>A large multi-center study was performed in Canada where data were collected from patients who were treated with intravenous acetylcysteine for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> between 1980 and 2005.  This study evaluated 4709 adult cases and 1905 pediatric cases.  The incidence of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> in adult (overall incidence 7.9%) and pediatric (overall incidence 9.5%) patients is presented in <a href="#t6">Tables 6</a> and <a href="#t7">7</a>.
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6. Distribution of reported reactions in adult patients receiving intravenous acetylcysteine
</span></caption>
<col align="left" width="58.950%">
<col align="left" width="41.050%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Incidence (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="Bold">Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="middle">% of Patients (n=4709)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>/<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Facial Flushing</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">6.1%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">4.3%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Respiratory Symptoms*
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.9%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.1%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.1%
</td>
</tr>
</tbody>
</table>
<a name="t7"></a><table width="100%">
<caption><span>Table 7. Distribution of reported reactions in pediatric patients receiving  intravenous acetylcysteine
</span></caption>
<col align="left" width="58.950%">
<col align="left" width="41.050%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote">*Respiratory symptoms are defined as presence of any of the following: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Incidence (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="Bold">Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="middle">% of Patients (n=1905)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>/<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Facial Flushing</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">7.6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">4.1%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Respiratory Symptoms*
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.2%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.1%
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s24"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First"> No drug-drug interaction studies have been conducted.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s25"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s26"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<p>There are no adequate and well-controlled studies of Acetadote in pregnant women.  However, limited case reports of pregnant women exposed to acetylcysteine during various trimesters did not report any adverse maternal, fetal or neonatal outcomes.
</p>
<p>There are published reports on four pregnant women with acetaminophen toxicity, who were treated with oral or intravenous acetylcysteine at the time of delivery.  Acetylcysteine crossed the placenta and was measurable following delivery in serum and cord blood of three viable infants and in cardiac blood of a fourth infant at autopsy (22 weeks gestational age who died 3Â hours after birth).  No adverse sequelae developed in the three viable infants.  All mothers recovered and none of the infants had evidence of acetaminophen <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.
</p>
<p>Reproduction studies were performed in rats at oral doses up to 2000 mg/kg/day (1.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface area comparison) and in rabbits at oral doses up to 1000 mg/kg/day (1.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface area comparison). No effects on fertility or harm to the fetus due to acetylcysteine were observed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s28"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing mothers
</h2>
<p class="First">It is not known whether Acetadote is present in human milk.  Because many drugs are excreted in human milk, caution should be exercised when acetylcysteine is administered to a nursing woman. Based on the pharmacokinetics of acetylcysteine, it should be nearly completely cleared 30 hours after administration.  Nursing women may consider resuming nursing 30 hours after administration.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s29"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric use
</h2>
<p class="First">No adverse effects were noted during intravenous infusion with acetylcysteine at a mean rate of 4.2 mg/kg/h for 24 hours to 10 preterm newborns ranging in gestational age from 25 to 31 weeks and in weight from 500 to 1380 grams in one study or in 6 newborns ranging in gestational age from 26 to 30 weeks and in weight from 520 to 1335 grams infused with acetylcysteine at 0.1 to 1.3 mg/kg/h for 6 days.  Elimination of acetylcysteine was slower in these infants than in adults; mean elimination half-life was 11 hours. There are no adequate and well-controlled studies in pediatric patients.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s30"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric use
</h2>
<p class="First">The clinical studies do not provide a sufficient number of geriatric subjects to determine whether the elderly respond differently.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s31"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">Single intravenous doses of acetylcysteine at 1000 mg/kg in mice, 2445 mg/kg in rats, 1500 mg/kg in guinea pigs, 1200 mg/kg in rabbits and 500 mg/kg in dogs were lethal.  Symptoms of acute toxicity were <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">labored respiration</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, loss of righting reflex and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s32"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">Acetylcysteine injection is an intravenous  antidote for the treatment of acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Acetylcysteine is the nonproprietary name for the N-acetyl derivative of the naturally occurring amino acid, L-cysteine (N-acetyl-L-cysteine).   The compound is a white crystalline powder, which melts in the range of 104Â° to 110Â°C and has a very slight odor.  The molecular formula of the compound is C<span class="Sub">5</span>H<span class="Sub">9</span>NO<span class="Sub">3</span>S, and its molecular weight is 163.2.  Acetylcysteine has the following structural formula:
</p>
<p><a name="f03"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39&amp;name=ace16-0008-03.jpg"></p>
<p>Acetadote is supplied as a sterile solution in vials containing 20% w/v (200Â mg/mL) acetylcysteine.  The pH of the solution ranges from 6.0 to 7.5.  Acetadote contains the following inactive ingredients: sodium hydroxide (used for pH adjustment), and Sterile Water for Injection, USP.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s33"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s34"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of action
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Underline">Acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span>:
</p>
<p>Acetaminophen is absorbed from the upper gastrointestinal tract with peak plasma levels occurring between 30 and 60 minutes after therapeutic doses and usually within 4 hours following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  It is extensively metabolized in the liver to form principally the sulfate and glucuronide conjugates which are excreted in the urine.  A small fraction of an ingested dose is metabolized in the liver by isozyme CYP2E1 of the cytochrome P-450 mixed function oxidase enzyme system to form a reactive, potentially toxic, intermediate metabolite. The toxic metabolite preferentially conjugates with hepatic glutathione to form nontoxic cysteine and mercapturic acid derivatives, which are then excreted by the kidney. Recommended therapeutic doses of acetaminophen are not believed to saturate the glucuronide and sulfate conjugation pathways and therefore are not expected to result in the formation of sufficient reactive metabolite to deplete glutathione stores.  However, following ingestion of a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the glucuronide and sulfate conjugation pathways are saturated resulting in a larger fraction of the drug being metabolized via the cytochrome P-450 pathway and therefore, the amount of acetaminophen metabolized to the reactive intermediate increases.  The increased formation of the reactive metabolite may deplete the hepatic stores of glutathione with subsequent binding of the metabolite to protein molecules within the hepatocyte resulting in cellular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Underline">Acetylcysteine Intravenous Treatment</span>:
</p>
<p> Acetylcysteine has been shown to reduce the extent of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> following acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  It is most effective when given early, with benefit seen principally in patients treated within 8-10 hours of the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s37"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Distribution</span>:
</p>
<p>The steady-state volume of distribution (Vd<span class="Sub">ss</span>) and the protein binding for acetylcysteine were reported to be 0.47 liter/kg and 83%, respectively.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span>:
</p>
<p>Acetylcysteine may form cysteine, disulfides and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine-cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc).  Based on published data, it was reported that after an oral dose of <span class="Sup">35</span>S-acetylcysteine, about 22% of total radioactivity was excreted in urine after 24 hours.  No metabolites were identified.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Underline">Elimination</span>:
</p>
<p>After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T<span class="Sub">1/2</span>) of 5.6 hours.  The mean clearance (CL) for acetylcysteine was reported to be 0.11 liter/hr/kg and renal CL constituted about 30% of total CL.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Underline">Special Populations</span>:
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-11.2.4.1"></a><p></p>
<p class="First"><span class="Italics">Gender:</span> Adequate information is not available to assess if there are differences in pharmacokinetics (PK) between males and females.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-11.2.4.2"></a><p></p>
<p class="First"><span class="Italics">Pediatric:</span> The mean elimination T<span class="Sub">1/2</span> of acetylcysteine is longer in newborns (11 hours) than in adults (5.6 hours).  Pharmacokinetic information is not available in other age groups.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-11.2.4.3"></a><p></p>
<p class="First"><span class="Italics">Pregnant Women:</span> In four pregnant women with acetaminophen toxicity, oral or intravenous acetylcysteine was administered at the time of delivery.  Acetylcysteine was detected in the cord blood of 3 viable infants and in cardiac blood of a fourth infant sampled at autopsy [<span class="Italics">see Pregnancy (<a href="#s26">8.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-11.2.4.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> In subjects with severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, i.e., cirrhosis due to alcohol (with Child-Pugh score of 7-13), or primary and/or secondary <span class="product-label-link" type="condition" conceptid="192675" conceptname="Biliary cirrhosis">biliary cirrhosis</span> (with Child-Pugh score of 5-7), mean T<span class="Sub">1/2</span> increased by 80% while mean CL decreased by 30% compared to the control group.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.2.4.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Pharmacokinetic information is not available in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-11.2.4.6"></a><p></p>
<p class="First"><span class="Italics">Geriatric Patients:</span> Adequate information on acetylcysteine PK in geriatric patients is not available.
</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s48"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s49"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential of acetylcysteine.
</p>
<p>Acetylcysteine was not genotoxic in the Ames test or the in vivo mouse micronucleus test. It was, however, positive in the in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK<span class="Sup">+/-</span>) forward mutation test.
</p>
<p>Treatment of male rats with acetylcysteine at an oral dose of 250 mg/kg/day for 15 weeks (0.1 times the recommended total human intravenous dose of 300 mg/kg based on body surface comparison) did not affect the fertility or general reproductive performance.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s50"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Underline">Loading Dose/Infusion Rate Study</span></p>
<p>A randomized, open-label, multi-center clinical study was conducted in Australia to compare the rates of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> between two rates of infusion for the intravenous acetylcysteine loading dose.  One hundred nine subjects were randomized to a 15 minute infusion rate and seventy-one subjects were randomized to a 60 minute infusion rate.  The loading dose was 150 mg/kg followed by a maintenance dose of 50 mg/kg over 4 hours and then 100 mg/kg over 16 hours.  Of the 180 patients, 27% were male and 73% were female.  Ages ranged from 15 to 83 years, with the mean age being 29.9 years (Â±13.0).
</p>
<p>A subgroup of 58 subjects (33 in the 15-minute treatment group; 25 in the 60-minute treatment group) was treated within 8 hours of acetaminophen ingestion.  No hepatotoxicity occurred within this subgroup; however with 95% confidence, the true hepatotoxicity rates could range from 0% to 9% for the 15-minute treatment group and from 0% to 12% for the 60-minute treatment group.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-13.2"></a><p></p>
<p class="First"><span class="Underline">Observational Study</span></p>
<p>An open-label, observational database contained information on 1749 patients who sought treatment for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> over a 16-year period.  Of the 1749 patients, 65% were female, 34% were male and less than 1% was transgender.  Ages ranged from 2 months to 96 years, with 71.4% of the patients <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> in the 16-40 year old age bracket. A total of 399 patients received acetylcysteine treatment.  A post-hoc analysis identified 56 patients who (1) were at high or probable risk for hepatotoxicity (APAP  greater than 150 mg/L at the four hours line according to the Australian nomogram) and (2) had a liver function test.  Of the 53 patients who were treated with intravenous acetylcysteine (300 mg/kg intravenous acetylcysteine administered over 20-21 hours) within 8 hours, two (4%) developed hepatotoxicity (AST or ALT greater than  1000 U/L).  Twenty-one of 48 (44%) patients treated with acetylcysteine after 15 hours developed hepatotoxicity. The actual number of hepatotoxicity outcomes may be higher than what is reported here. For patients with multiple admissions for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, only the first <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treated with intravenous acetylcysteine was examined. Hepatotoxicity may have occurred in subsequent admissions.
</p>
<p>Evaluable data were available from a total of 148 pediatric patients (less than 16 years of age) who were admitted for <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> following ingestion of acetaminophen, of whom 23 were treated with intravenous acetylcysteine.  Of the 23 patients who received intravenous acetylcysteine treatment, 3 patients (13%) had an adverse reaction (<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, transient <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>).  There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> of pediatric patients.  None of the pediatric patients receiving intravenous acetylcysteine developed hepatotoxicity while two patients not receiving intravenous acetylcysteine developed hepatotoxicity.  The number of pediatric patients is too small to provide a statistically significant finding of efficacy; however the results appear to be consistent to those observed for adults.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-13.3"></a><p></p>
<p class="First"><span class="Underline">Postmarketing Safety Study</span> [<span class="Italics">see <a href="#s21">6.1</a> Clinical Studies Experience</span>]
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s54"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Acetadote (acetylcysteine) Injection is available as a 20% solution (200mg/mL) in 30 mL single dose glass vials. Each single dose vial contains 6g/30mL (200 mg/mL) of Acetadote Injection. Acetadote is sterile and can be used for intravenous administration.  It is available as follows:
</p>
<ul class="Disc"><li>30 mL vials, carton of 4 (NDC 66220-207-30)
</li></ul>
<p>Do not use previously opened vials for intravenous administration.
</p>
<p><span class="Bold">Note:</span>  The color of Acetadote may turn from essentially colorless to a slight pink or purple once the stopper is punctured.  The color change does not affect the quality of the product.
</p>
<p>The stopper in the Acetadote vial is formulated with a synthetic base-polymer and does not contain Natural Rubber Latex, Dry Natural Rubber, or blends of Natural Rubber.
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s55"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store unopened vials at controlled room temperature, 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s56"></a><a name="section-15"></a><p></p>
<h1>17   PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Sensitivity to acetylcysteine: Patients should be advised to report to their physician any history of sensitivity to acetylcysteine [<span class="Italics">see Contraindications (<a href="#s15">4</a>)</span>].
</p>
<p><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>: Patients should be advised to report to their physician any history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> [<span class="Italics">see Warnings and Precautions (<a href="#s16">5</a>)</span>].
</p>
<p>For all questions concerning adverse reactions associated with the use of this product or for inquiries concerning our products, please contact us at 1-877-484-2700.
</p>
<p>For specific treatment information regarding the clinical management of acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, please contact your regional poison center at 1-800-222-1222, or alternatively, a special health professional assistance line for acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> at 1-800-525-6115.
</p>
<p>Manufactured for:<br>Cumberland Pharmaceuticals Inc.<br>Nashville, TN 37203
</p>
<p>*Sections or subsections omitted from the Full Prescribing Information are not listed.
</p>
<p>US Patent Nos. 8,148,356 and 8,399,445.  Patents pending.
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s57"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL â€“ Vial Label</span></p>
<p>30 mL     NDC 66220-207-30<br>Sterile
</p>
<p><span class="Bold">Acetadote</span><span class="Bold"><span class="Sup">Â®</span></span><br><span class="Bold">(acetylcysteine) Injection</span></p>
<p><span class="Bold">6 g/30 mL<br></span>(200 mg/mL)
</p>
<p><span class="Bold">MUST BE FURTHER DILUTED<br>PRIOR TO INTRAVENOUS USE</span></p>
<p><span class="Bold">CUMBERLAND</span><span class="Bold"><span class="Sup">Â®</span></span></p>
<p>PHARMACEUTICALS
</p>
<div class="Figure">
<a name="f04"></a><img alt="PRINCIPAL DISPLAY PANEL â€“ Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39&amp;name=ace16-0008-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s58"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL â€“ Carton Label</span></p>
<p>4 Ã— 30mL Sterile Vials  NDC 66220-207-30
</p>
<p><span class="Bold">Acetadote</span><span class="Bold"><span class="Sup">Â®</span></span><br><span class="Bold">(acetylcysteine) Injection</span></p>
<p><span class="Bold">6 g/30 mL<br></span>(200 mg/mL)
</p>
<p><span class="Bold">MUST BE FURTHER DILUTED<br>PRIOR TO INTRAVENOUS USE</span></p>
<p><span class="Bold">CUMBERLAND</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold"><br></span>PHARMACEUTICALS
</p>
<p>Manufactured for:<br>Cumberland Pharmaceuticals Inc.<br>Nashville, TN, USA, 37203
</p>
<p>Made in USA
</p>
<div class="Figure">
<a name="f05"></a><img alt="PRINCIPAL DISPLAY PANEL â€“ Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39&amp;name=ace16-0008-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACETADOTEÂ 		
					</strong><br><span class="contentTableReg">acetylcysteine injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66220-207</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Acetylcysteine</strong> (Acetylcysteine) </td>
<td class="formItem">Acetylcysteine</td>
<td class="formItem">200Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66220-207-30</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021539</td>
<td class="formItem">01/22/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Cumberland Pharmaceuticals Inc.
							(069532880)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>74796172-7d5d-4e77-beec-fcde5c1b5cab</div>
<div>Set id: 472f158a-5ab9-4308-8e49-1116e6ea3d39</div>
<div>Version: 5</div>
<div>Effective Time: 20130605</div>
</div>
</div>Â <div class="DistributorName">Cumberland Pharmaceuticals Inc.</div></p>
</body></html>
